Kaveri Seed Company Ltd
KSCLKaveri Seed Company Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.
The sharpest disagreement: annual EPS moved +5.2% against a −37.5% price move — the market has not yet caught up with the delivery.
The price is in a downtrend (49 weeks in) while the P/E sits at the 45th percentile of its own 11-year range. Underneath, the last four quarters read deteriorating — profit −14.4% year on year, and 66% of the last 3 years' profit arrived as cash. What settles it: whether the price catches up with earnings that have already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Kaveri Seed Company Ltd trades at ₹716, in a downtrend and 49 weeks into that stage. That is −18.8% against its own 200-day average. It sits at 0% of a 52-week range of ₹716 to ₹1,070. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (16 weeks and counting).
Today the stock is in a downtrend — week 49 of stage 4, confirmed. At ₹716 it trades −18.8% versus its 200-day average and sits at 0% of its 52-week range (₹716–₹1,070).
Against the market, two honest reads. Cumulative: over the last 10.5 years the stock moved +82% while the NIFTY 500 moved +267% — behind the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (16 weeks and counting; last ahead the week of 2026-06-12) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Kaveri Seed Company Ltd trades at 14.8× P/E, mid-range by its own standards (45th percentile). Its long-run median P/E is 15.2×, measured across 10.5 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 14.8× is mid-range by its own standards (45th percentile), against a long-run median of 15.2× measured over 10.5 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved +5.2% against a −37.5% price move — earnings outran the price, pushing the multiple DOWN its own range.
The price move, decomposed: over 5y, of the +3.5%/yr price move, ~+5.9%/yr came from earnings growth and ~−2.4 pp from the multiple (compressing); over 10y, of the +7.3%/yr price move, ~+7.1%/yr came from earnings growth and ~+0.2 pp from the multiple (roughly flat). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: Deteriorating Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Kaveri Seed Company Ltd reads as deteriorating on its fundamental arc. Deteriorating — profit and EPS growth are shrinking (profit growth −21.7% latest against +26.9% at its 12-quarter best), ROCE slipping at 18.2%. The read is built from 12 quarters across 4 curves, on full evidence.
🚨 Why it matters: falling curves mean every cheap-looking ratio below needs a discount for direction.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +16.1% | +9.3% | +6.2% | +6.5% |
| Profit | +5.0% | +2.7% | −1.0% | +5.9% |
| EPS | +5.2% | +5.8% | +2.2% | +9.0% |
| Share price | −37.5% | +8.0% | +3.5% | +7.3% |
4-Factor Sector Score
35.9/100 — rank 24 of 36 in Miscellaneous · 94% evidence confidence
Kaveri Seed Company Ltd scores 35.9 out of 100 against the 36 companies it is compared with in Miscellaneous, ranking 24. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 11.3 + 14.4 + 4.7 + 5.5 = 35.9. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Kaveri Seed Company Ltd reported ₹742 Cr of revenue in the Jun 26 quarter, −13.6% year on year. Over 10 years it has compounded at 6.5% a year. The last full year, FY26, came in at ₹1,395 Cr. The last four reported quarters add to ₹1,278 Cr.
FY26 revenue came in at ₹1,395 Cr (+16.1% on the year), capping 10 years at 6.5% compound. The latest quarter (Jun 26) printed ₹742 Cr, −13.6% year on year.
Pace check: the last four quarters averaged +21.5% growth against the decade's 6.5% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +1.4% over the last 4 quarters against +2.6%/yr over the last 8 — stabilising; TTM profit −21.7% vs −11.2%/yr — rolling over.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Kaveri Seed Company Ltd's operating margin is 40.0% in the Jun 26 quarter, +1.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 20.0% to 29.0%. The current quarter is running above every full year in that window.
The latest quarter's operating margin is 40.0%, +1.0 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 20.0%–29.0%.
Why the margin moved: operating margin went +0.2 pp year on year while gross margin went +3.6 pp — the gain came mostly from the gross line: input costs and pricing.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Kaveri Seed Company Ltd earned ₹280 Cr of net profit in the Jun 26 quarter, −14.4% year on year. Full-year FY26 profit was ₹296 Cr. The 10-year compound rate is 5.9%. That is 37.7% of the quarter's revenue. The same quarter a year earlier earned ₹327 Cr. 4 of the last 12 reported quarters were loss-making.
Jun 26 profit was ₹280 Cr, −14.4% year on year. On the full year, FY26 printed ₹296 Cr (+5.0%), and the 10-year compound rate is 5.9%.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 66% of Kaveri Seed Company Ltd's reported profit arrived as operating cash — most of the profit is real cash. In FY26 that was ₹−6.0 Cr of operating cash against ₹296 Cr of profit. After ₹115 Cr of capital spending, ₹−121 Cr was left as free cash.
FY26: operating cash of ₹−6.0 Cr against reported profit of ₹296 Cr, leaving free cash of ₹−121 Cr after ₹115 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 66% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
🚨 Why conversion sits at 66%: the cash cycle stretched 115 days between FY21 and FY26 — more of each rupee of profit waits inside the cycle before arriving. Less than 70% of profit arriving as cash is the thing to watch on this page.
Router verdict: conversion is below par and the cash cycle has stretched 115 days — the next section's job is to find where the cash is stuck.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Kaveri Seed Company Ltd's cash conversion cycle runs 396 days in FY26, up from 281 days in FY21. Capital spending ran ₹296 Cr over the last 3 years. At FY26 sales of ₹1,395 Cr each day of that cycle holds about ₹3.8 Cr, so roughly ₹1,513 Cr sits inside the business at any moment.
FY26: debtors at 29 days, inventory at 608 days — roughly 20.0 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 396 days, looser than FY21's 281.
The full loop: cash goes out to suppliers and production on day 0; stock waits 608 days to sell; customers pay about 29 days after that; and suppliers themselves are paid at 241 days — netting out to the 396-day cycle.
In money terms: at FY26 sales of ₹1,395 Cr, each day of the cycle holds about ₹3.8 Cr — so the 396-day loop keeps roughly ₹1,513 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹296 Cr over the last 3 fiscal years against ₹128 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹130 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the working-capital loop is the cash sink the router flagged — watch the cycle, not the P&L.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Kaveri Seed Company Ltd earns a ROCE of 19% in FY26. That is up from a trough of 15% in FY17. Return on invested capital clears the cost of that capital by +5.2 percentage points, so growth here adds value rather than only size. The wiring behind it is 21.2% net margin on 0.51× asset turns.
FY26 ROCE is 19%, recovered from a FY17 trough of 15% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY26): 21.2% net margin × 0.51× asset turns × 1.57× balance-sheet leverage ≈ 17.0% on equity. Margin is doing the heavy lifting; leverage is modest — this is an earned return, not a borrowed one.
The capstone test — ROIC − WACC: 17.2% − 12.0% = a +5.2 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. A spread this wide means every rupee reinvested creates more than a rupee of value — the engine compounds.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Kaveri Seed Company Ltd carries total debt of ₹0.0 Cr against shareholder equity of ₹1,236 Cr as of Jun 24, a debt-to-equity of 0.00 — effectively unlevered. On the annual view that ratio went from 0.00 in FY22 to 0.00 in FY24. The returns elsewhere on this page are therefore earned rather than borrowed.
Jun 24: total debt of ₹0.0 Cr against shareholder equity of ₹1,236 Cr — a debt-to-equity of 0.00. On the annual view, debt-to-equity went from 0.00 (FY22) to 0.00 (FY24). The returns on this page are earned, not borrowed.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Domestic institutions cut 1.5 points of Kaveri Seed Company Ltd over 8 quarters, the biggest move on the register. That takes domestic institutions to 3.5% of the company. Foreign institutions moved −1.4 points over the same window, to 17.5%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Domestic institutions: −1.5 points over 8 quarters to 3.5%; Foreign institutions: −1.4 points over 8 quarters to 17.5%; Promoters: +0.0 points over 8 quarters to 60.5%.
🚨 Why the register moved: domestic institutions drove it (−1.5 points), alongside foreign institutions (−1.4 points) — distribution into the market’s bid.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Kaveri Seed Company Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Gulshan Polyols LtdGULPOLY | 70.7/100Favorable setup87% evidence | ASLEEP | 27.5/35 Revenue 9.4% · PAT 100% · OPM change 7 pp 95% evidence | 19.2/25 ROCE 18.6% · OPM 13% 95% evidence | 13.2/20 P/E 7.4× · PEG — 50% evidence | 10.8/20 RS sector 3.7% · RS bench 7% · 1Y 8.8%5 of 12 weeks ahead 100% evidence |
| Exact sum: 27.5 + 19.2 + 13.2 + 10.8 = 70.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 2Sagility LtdSAGILITY | 67.6/100Favorable setup87% evidence | TURNING | 24.7/35 Revenue 29.4% · PAT 49.3% · OPM change 0 pp 100% evidence | 15.8/25 ROCE 13.4% · OPM 22% 100% evidence | 13.5/20 P/E 20.6× · PEG 1.08 65% evidence | 13.6/20 RS sector 7.2% · RS bench 1.7% · 1Y 5.3%3 of 10 weeks ahead 70% evidence |
| Exact sum: 24.7 + 15.8 + 13.5 + 13.6 = 67.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3IIRM Holdings India Ltd526530 | 64.2/100Mixed-positive evidence75% evidence | LEADER | 16.3/35 Revenue 14.9% · PAT 12.7% · OPM change 1.1 pp 95% evidence | 19.0/25 ROCE 20.4% · OPM 24.6% 76% evidence | 9.9/20 P/E 39.9× · PEG — 15% evidence | 19.0/20 RS sector 42.8% · RS bench 47.3% · 1Y 79.1%11 of 12 weeks ahead 100% evidence |
| Exact sum: 16.3 + 19 + 9.9 + 19 = 64.2 · Decision use: Price leads the evidence: RS versus the benchmark is 47.3%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 4Exhicon Events Media Solutions Ltd543895 | 63.7/100Thin evidence · provisional60% evidence | TURNING | 19.0/35 Revenue 100% · PAT 100% · OPM change 0 pp 48% evidence | 20.1/25 ROCE 29.5% · OPM 28% 76% evidence | 13.4/20 P/E 19.2× · PEG — 50% evidence | 11.2/20 RS sector 2.2% · RS bench -1.9% · 1Y -4.8%2 of 10 weeks ahead 70% evidence |
| Exact sum: 19 + 20.1 + 13.4 + 11.2 = 63.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 5Aeroflex Enterprises LtdAEROENTER | 62.8/100Mixed-positive evidence87% evidence | LEADER | 19.7/35 Revenue 27.5% · PAT 100% · OPM change -5 pp 95% evidence | 14.9/25 ROCE 12.6% · OPM 9% 95% evidence | 9.0/20 P/E 10.2× · PEG — 50% evidence | 19.2/20 RS sector 38.8% · RS bench 42.9% · 1Y 57.7%12 of 12 weeks ahead 100% evidence |
| Exact sum: 19.7 + 14.9 + 9 + 19.2 = 62.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Global Education LtdGLOBAL | 62.5/100Mixed-positive evidence80% evidence | TURNING | 14.2/35 Revenue 28.2% · PAT 3.3% · OPM change 0.3 pp 95% evidence | 19.8/25 ROCE 29.2% · OPM 41% 95% evidence | 10.1/20 P/E 24.8× · PEG — 15% evidence | 18.4/20 RS sector 32.4% · RS bench 36.9% · 1Y 97.6%2 of 12 weeks ahead 100% evidence |
| Exact sum: 14.2 + 19.8 + 10.1 + 18.4 = 62.5 · Decision use: Price leads the evidence: RS versus the benchmark is 36.9%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 7Take Solutions LtdTAKE | 58.7/100Thin evidence · provisional57% evidence | 24.7/35 Revenue — · PAT 100% · OPM change 2932.2 pp 57% evidence | 8.5/25 ROCE 11.2% · OPM — 80% evidence | 8.5/20 P/E 3222× · PEG — 15% evidence | 17.0/20 RS sector 71.1% · RS bench 71.4% · 1Y 300.4%11 of 12 weeks ahead to 2026-05-03 70% evidence | |
| Exact sum: 24.7 + 8.5 + 8.5 + 17 = 58.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 8R K Swamy LtdRKSWAMY | 57.1/100Mixed-positive evidence65% evidence | 22.5/35 Revenue 14.3% · PAT 17.3% · OPM change 2.6 pp 95% evidence | 15.6/25 ROCE 12.3% · OPM 10.4% 95% evidence | 10.7/20 P/E 19.5× · PEG — 15% evidence | 8.3/20 RS sector — · RS bench -16.7% · 1Y —4 of 5 weeks ahead to 2026-08-16 25% evidence | |
| Exact sum: 22.5 + 15.6 + 10.7 + 8.3 = 57.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9Aegis Vopak Terminals LtdAEGISVOPAK | 55.8/100Mixed-positive evidence60% evidence | BREAKING OUT | 21.9/35 Revenue 25.9% · PAT 40.9% · OPM change 2 pp 95% evidence | 13.2/25 ROCE 7.6% · OPM 77% 76% evidence | 8.9/20 P/E 121× · PEG — 15% evidence | 11.8/20 RS sector — · RS bench 25.5% · 1Y 24.5%10 of 10 weeks ahead 25% evidence |
| Exact sum: 21.9 + 13.2 + 8.9 + 11.8 = 55.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10Parin Enterprises LtdPARIN | 52.2/100Mixed-positive evidence63% evidence | FADING | 19.4/35 Revenue 100% · PAT 100% · OPM change -3 pp 48% evidence | 11.6/25 ROCE 10.8% · OPM 9% 95% evidence | 9.1/20 P/E 117× · PEG — 15% evidence | 12.1/20 RS sector 5.1% · RS bench 8.7% · 1Y 46.8%8 of 12 weeks ahead 100% evidence |
| Exact sum: 19.4 + 11.6 + 9.1 + 12.1 = 52.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Eveready Industries India LtdEVEREADY | 50.9/100Mixed-positive evidence94% evidence | TURNING | 18.9/35 Revenue 8.7% · PAT 100% · OPM change 1 pp 100% evidence | 13.6/25 ROCE 17.2% · OPM 15% 100% evidence | 9.0/20 P/E 16.6× · PEG 2.1 100% evidence | 9.4/20 RS sector -9.5% · RS bench 8.6% · 1Y -22.3%6 of 10 weeks ahead 70% evidence |
| Exact sum: 18.9 + 13.6 + 9 + 9.4 = 50.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 12GMR Airports LtdGMRAIRPORT | 50.8/100Mixed-positive evidence74% evidence | ASLEEP | 22.7/35 Revenue 38.8% · PAT 100% · OPM change 1 pp 74% evidence | 11.3/25 ROCE 11.6% · OPM 37% 100% evidence | 8.7/20 P/E 184× · PEG — 15% evidence | 8.1/20 RS sector -2.8% · RS bench 0.5% · 1Y 14%6 of 12 weeks ahead 100% evidence |
| Exact sum: 22.7 + 11.3 + 8.7 + 8.1 = 50.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 13Anzen India Energy Yield Plus TrustANZEN | 50.3/100Mixed-positive evidence60% evidence | TURNING | 20.7/35 Revenue 100% · PAT 100% · OPM change -9 pp 95% evidence | 9.1/25 ROCE 3.3% · OPM 80% 76% evidence | 9.3/20 P/E 99.7× · PEG — 15% evidence | 11.2/20 RS sector — · RS bench 7.3% · 1Y 8.7%1 of 10 weeks ahead 25% evidence |
| Exact sum: 20.7 + 9.1 + 9.3 + 11.2 = 50.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14Jai Corp LtdJAICORPLTD | 48.3/100Mixed-negative evidence74% evidence | BASING | 19.6/35 Revenue 2.7% · PAT -40.4% · OPM change 9 pp 95% evidence | 11.4/25 ROCE 11.8% · OPM 15% 95% evidence | 10.9/20 P/E 17.8× · PEG — 15% evidence | 6.4/20 RS sector -8.2% · RS bench -19.2% · 1Y -40.2%1 of 10 weeks ahead 70% evidence |
| Exact sum: 19.6 + 11.4 + 10.9 + 6.4 = 48.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15Inox Green Energy Services LtdINOXGREEN | 48.0/100Mixed-negative evidence75% evidence | ASLEEP | 22.2/35 Revenue 16.5% · PAT 100% · OPM change -13.2 pp 95% evidence | 9.1/25 ROCE 8.4% · OPM -2.2% 76% evidence | 9.7/20 P/E 58.4× · PEG — 15% evidence | 7.0/20 RS sector -6% · RS bench -2.9% · 1Y 19.3%5 of 12 weeks ahead 100% evidence |
| Exact sum: 22.2 + 9.1 + 9.7 + 7 = 48 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16TCC Concept LtdTCC | 47.5/100Mixed-negative evidence81% evidence | BASING | 16.6/35 Revenue 100% · PAT 51.1% · OPM change -45 pp 95% evidence | 11.8/25 ROCE 5.7% · OPM 36% 95% evidence | 14.1/20 P/E 20× · PEG — 50% evidence | 5.0/20 RS sector -17.6% · RS bench -31.9% · 1Y -89.7%0 of 11 weeks ahead 70% evidence |
| Exact sum: 16.6 + 11.8 + 14.1 + 5 = 47.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17Prozone Realty LtdPROZONER | 46.4/100Mixed-negative evidence80% evidence | TURNING | 17.0/35 Revenue -9.9% · PAT 100% · OPM change 8.2 pp 95% evidence | 6.4/25 ROCE -1% · OPM -35.6% 95% evidence | 9.6/20 P/E 62.1× · PEG — 15% evidence | 13.4/20 RS sector -0.3% · RS bench 3.1% · 1Y 21.7%1 of 12 weeks ahead 100% evidence |
| Exact sum: 17 + 6.4 + 9.6 + 13.4 = 46.4 · Decision use: Price leads the evidence: RS versus the benchmark is 3.1%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 18Aqylon Nexus LtdAQYLON | 45.9/100Mixed-negative evidence72% evidence | BASING | 18.5/35 Revenue 100% · PAT 100% · OPM change 2358 pp 71% evidence | 18.8/25 ROCE 131% · OPM 58% 95% evidence | 8.6/20 P/E 759× · PEG — 15% evidence | 0.0/20 RS sector -76.3% · RS bench -75.3% · 1Y -79.6%0 of 12 weeks ahead 100% evidence |
| Exact sum: 18.5 + 18.8 + 8.6 + 0 = 45.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 19Jindal Photo LtdJINDALPHOT | 43.3/100Mixed-negative evidence77% evidence | ASLEEP | 20.4/35 Revenue 100% · PAT -80% · OPM change 15 pp 95% evidence | 10.1/25 ROCE -1.4% · OPM 98% 95% evidence | 10.0/20 P/E — · PEG — 0% evidence | 2.8/20 RS sector -19.1% · RS bench -16.2% · 1Y -14.4%1 of 12 weeks ahead 100% evidence |
| Exact sum: 20.4 + 10.1 + 10 + 2.8 = 43.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 20Shipping Corporation of India Land & Assets LtdSCILAL | 42.8/100Mixed-negative evidence80% evidence | BASING | 24.2/35 Revenue 23.8% · PAT 100% · OPM change 13 pp 95% evidence | 5.0/25 ROCE 1.3% · OPM -14% 95% evidence | 9.5/20 P/E 62.3× · PEG — 15% evidence | 4.1/20 RS sector -17.6% · RS bench -14.8% · 1Y -26.8%2 of 12 weeks ahead 100% evidence |
| Exact sum: 24.2 + 5 + 9.5 + 4.1 = 42.8 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -17.6% and the one-year return is -26.8%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 21TruAlt Bioenergy LtdTRUALT | 40.3/100Mixed-negative evidence63% evidence | ASLEEP | 10.7/35 Revenue 1.8% · PAT -8.1% · OPM change 7 pp 100% evidence | 9.3/25 ROCE 10.4% · OPM 21% 100% evidence | 10.3/20 P/E 22.8× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y -21.6%2 of 12 weeks ahead 0% evidence |
| Exact sum: 10.7 + 9.3 + 10.3 + 10 = 40.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 22GKW LtdGKWLIMITED | 39.2/100Mixed-negative evidence71% evidence | ASLEEP | 10.9/35 Revenue -13.5% · PAT 0% · OPM change -2 pp 95% evidence | 9.2/25 ROCE 0.5% · OPM 84% 95% evidence | 10.0/20 P/E — · PEG — 0% evidence | 9.1/20 RS sector -0.9% · RS bench -4.5% · 1Y -9.4%2 of 10 weeks ahead 70% evidence |
| Exact sum: 10.9 + 9.2 + 10 + 9.1 = 39.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 23Unitech LtdUNITECH | 36.8/100Mixed-negative evidence69% evidence | BASING | 18.0/35 Revenue 45.3% · PAT -10% · OPM change 15 pp 71% evidence | 3.5/25 ROCE 0.1% · OPM 6% 95% evidence | 10.0/20 P/E — · PEG — 0% evidence | 5.3/20 RS sector -22.3% · RS bench -19.7% · 1Y -39.9%2 of 12 weeks ahead 100% evidence |
| Exact sum: 18 + 3.5 + 10 + 5.3 = 36.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 24Kaveri Seed Company Ltdthis pageKSCL | 35.9/100Mixed-negative evidence94% evidence | BASING | 11.3/35 Revenue 1.4% · PAT -21.7% · OPM change 1 pp 100% evidence | 14.4/25 ROCE 18.8% · OPM 40% 100% evidence | 4.7/20 P/E 14.8× · PEG 3.12 100% evidence | 5.5/20 RS sector -17.2% · RS bench -19.8% · 1Y -40%1 of 11 weeks ahead 70% evidence |
| Exact sum: 11.3 + 14.4 + 4.7 + 5.5 = 35.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 25Delta Corp LtdDELTACORP | 35.4/100Mixed-negative evidence81% evidence | BASING | 9.7/35 Revenue -9.3% · PAT -80% · OPM change -3 pp 95% evidence | 8.6/25 ROCE 5.1% · OPM 18% 95% evidence | 12.0/20 P/E 9.4× · PEG — 50% evidence | 5.1/20 RS sector -18.1% · RS bench -18.3% · 1Y -36.2%1 of 10 weeks ahead 70% evidence |
| Exact sum: 9.7 + 8.6 + 12 + 5.1 = 35.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 26Stanley Lifestyles LtdSTANLEY | 30.0/100Adverse evidence74% evidence | BASING | 6.6/35 Revenue -5.6% · PAT -80% · OPM change -3.4 pp 95% evidence | 10.8/25 ROCE 6.4% · OPM 17.3% 95% evidence | 9.2/20 P/E 112× · PEG — 15% evidence | 3.4/20 RS sector -43.7% · RS bench -25.2% · 1Y -54.7%3 of 10 weeks ahead 70% evidence |
| Exact sum: 6.6 + 10.8 + 9.2 + 3.4 = 30 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 27Embassy Developments LtdEMBDL | 26.2/100Adverse evidence64% evidence | BASING | 5.9/35 Revenue -46.6% · PAT -80% · OPM change -58.4 pp 71% evidence | 3.4/25 ROCE -2.4% · OPM -60% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 6.9/20 RS sector -18.4% · RS bench -15.8% · 1Y -42.9%6 of 12 weeks ahead 100% evidence |
| Exact sum: 5.9 + 3.4 + 10 + 6.9 = 26.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 28RattanIndia Enterprises LtdRTNINDIA | 17.5/100Adverse evidence74% evidence | ASLEEP | 2.7/35 Revenue 2.1% · PAT -80% · OPM change -23.9 pp 100% evidence | 1.0/25 ROCE -4.8% · OPM 2.1% 100% evidence | 10.0/20 P/E — · PEG — 0% evidence | 3.8/20 RS sector -32.1% · RS bench -24.4% · 1Y -55.3%1 of 10 weeks ahead 70% evidence |
| Exact sum: 2.7 + 1 + 10 + 3.8 = 17.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 29Central Mine Planning & Design Institute LtdCMPDI | 63.2/100Thin evidence · provisional40% evidence | ASLEEP | 22.4/35 Revenue — · PAT — · OPM change 8 pp 34% evidence | 20.6/25 ROCE 38.1% · OPM 30% 100% evidence | 10.2/20 P/E 23.5× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —4 of 9 weeks ahead 0% evidence |
| Exact sum: 22.4 + 20.6 + 10.2 + 10 = 63.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 30FlySBS Aviation LtdFLYSBS | 57.7/100Thin evidence · provisional41% evidence | BREAKING OUT | 15.4/35 Revenue — · PAT — · OPM change -8 pp 26% evidence | 19.4/25 ROCE 32.5% · OPM 21% 95% evidence | 10.6/20 P/E 20× · PEG — 15% evidence | 12.3/20 RS sector — · RS bench 43.9% · 1Y 14.1%6 of 10 weeks ahead 25% evidence |
| Exact sum: 15.4 + 19.4 + 10.6 + 12.3 = 57.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 31Qualitek Labs Ltd544091 | 54.3/100Thin evidence · provisional29% evidence | BREAKING OUT | 17.3/35 Revenue — · PAT — · OPM change -3 pp 7% evidence | 15.1/25 ROCE 11.9% · OPM 26% 76% evidence | 9.8/20 P/E 44.2× · PEG — 15% evidence | 12.1/20 RS sector — · RS bench 42.7% · 1Y —4 of 6 weeks ahead 25% evidence |
| Exact sum: 17.3 + 15.1 + 9.8 + 12.1 = 54.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 32Shree Vasu Logistics LtdSVLL | 52.6/100Thin evidence · provisional50% evidence | BREAKING OUT | 18.3/35 Revenue — · PAT — · OPM change 0.8 pp 26% evidence | 16.0/25 ROCE 12.9% · OPM 25.8% 95% evidence | 8.8/20 P/E 126× · PEG — 15% evidence | 9.5/20 RS sector -16.1% · RS bench 17.5% · 1Y 2.2%10 of 10 weeks ahead 70% evidence |
| Exact sum: 18.3 + 16 + 8.8 + 9.5 = 52.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 33Indiqube Spaces LtdINDIQUBE | 49.7/100Thin evidence · provisional49% evidence | BREAKING OUT | 18.9/35 Revenue 38.9% · PAT 30.4% · OPM change 0 pp 71% evidence | 9.3/25 ROCE 6.4% · OPM 61% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 11.5/20 RS sector — · RS bench 10.4% · 1Y -11.8%5 of 10 weeks ahead 25% evidence |
| Exact sum: 18.9 + 9.3 + 10 + 11.5 = 49.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 34Maagh Advertising & Marketing Services Ltd543624 | 49.5/100Thin evidence · provisional35% evidence | 18.4/35 Revenue — · PAT — · OPM change 275.6 pp 32% evidence | 9.1/25 ROCE -0.4% · OPM 55.6% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 12.0/20 RS sector — · RS bench 37% · 1Y —7 of 9 weeks ahead to 2025-03-19 25% evidence | |
| Exact sum: 18.4 + 9.1 + 10 + 12 = 49.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 35Tandhan Industries Ltd512062 | 46.3/100Thin evidence · provisional33% evidence | BREAKING OUT | 20.2/35 Revenue — · PAT 100% · OPM change — 33% evidence | 6.7/25 ROCE -0.3% · OPM 15.8% 76% evidence | 9.4/20 P/E 71.2× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —10 of 10 weeks ahead 0% evidence |
| Exact sum: 20.2 + 6.7 + 9.4 + 10 = 46.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 36Shree Rama Newsprint LtdRAMANEWS | 45.4/100Thin evidence · provisional46% evidence | 14.1/35 Revenue -20% · PAT 69.8% · OPM change -8 pp 40% evidence | 6.1/25 ROCE 1.9% · OPM 8% 71% evidence | 10.0/20 P/E — · PEG — 0% evidence | 15.2/20 RS sector 9.7% · RS bench 10.5% · 1Y 21.7%11 of 12 weeks ahead to 2026-04-19 70% evidence | |
| Exact sum: 14.1 + 6.1 + 10 + 15.2 = 45.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Kaveri Seed Company Ltd's share price today?
Kaveri Seed Company Ltd trades at ₹716, −37.5% over the past year. The company is valued at ₹3,682 Cr. The stock sits at the very bottom of its 52-week range (₹716–₹1,070), −18.8% versus its 200-day average. On the tape, the price is in a downtrend, 49 weeks in. — as of 11 September 2026.
What were Kaveri Seed Company Ltd's latest quarterly results?
Kaveri Seed Company Ltd reported revenue of ₹742 Cr and net profit of ₹280 Cr for the Jun 26 quarter. Revenue fell 13.6% and profit fell 14.4% year on year. Earnings per share were ₹54.40. The operating margin was 40.0%, 1.0 pp higher than a year earlier. — as of 11 September 2026.
What is Kaveri Seed Company Ltd's revenue?
Kaveri Seed Company Ltd reported revenue of ₹742 Cr in the Jun 26 quarter, −13.6% year on year. For the full FY26 fiscal year, revenue was ₹1,395 Cr (+16.1%). Over the last 10 years revenue compounded at 6.5% a year. — as of 11 September 2026.
What is Kaveri Seed Company Ltd's profit?
Kaveri Seed Company Ltd earned ₹280 Cr of net profit in the Jun 26 quarter, −14.4% year on year. Full-year FY26 profit was ₹296 Cr. The operating margin ran 40.0% in the latest quarter. — as of 11 September 2026.
What is Kaveri Seed Company Ltd's market cap?
Kaveri Seed Company Ltd's market capitalisation is ₹3,682 Cr at a share price of ₹716. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 11 September 2026.
What is Kaveri Seed Company Ltd's P/E ratio?
Kaveri Seed Company Ltd trades at a P/E of 14.8×, at the 45th percentile of its own 11-year range, against a long-run median of 15.2×. This is a comparison with the stock's own history, not a value call — as of 11 September 2026.
Does Kaveri Seed Company Ltd pay a dividend?
Yes — Kaveri Seed Company Ltd's dividend payout was 9% of profit in FY26, and it recorded a payout in 12 of its last 13 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 11 September 2026.
Is Kaveri Seed Company Ltd overvalued?
On its own history, Kaveri Seed Company Ltd looks mid-range: its P/E of 14.8× sits at the 45th percentile of its 11-year range (long-run median 15.2×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 11 September 2026.
Is Kaveri Seed Company Ltd growing?
Not right now — Kaveri Seed Company Ltd's latest numbers are shrinking: latest-quarter revenue −13.6% year on year, profit −14.4%, and the margin +1.0 pp at 40.0%. The 10-year compound rates are 6.5% (revenue) and 5.9% (profit). The earnings engine currently reads: deteriorating — as of 11 September 2026.
How is Kaveri Seed Company Ltd performing?
Kaveri Seed Company Ltd is in a downtrend, 49 weeks in. Its latest quarter's revenue fell 13.6% and profit fell 14.4% year on year. Against the NIFTY 500 it has been behind on a trailing-13-week view for 16 weeks. This describes what the data did, not a rating. — as of 11 September 2026.
What stage is Kaveri Seed Company Ltd in?
Deteriorating — profit and EPS growth are shrinking (profit growth −21.7% latest against +26.9% at its 12-quarter best), ROCE slipping at 18.2%. The read comes from the last 12 quarters of growth (revenue growth +1.4% latest, profit growth −21.7% latest, eps growth −21.5% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 11 September 2026.
Is Kaveri Seed Company Ltd in an uptrend?
No — the price is in a downtrend (week 49 of stage 4), trading −18.8% versus its 200-day average and at the very bottom of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 11 September 2026.
Is Kaveri Seed Company Ltd beating the market?
Not lately — on a trailing-13-week view Kaveri Seed Company Ltd is currently behind the NIFTY 500 (16 weeks and counting; last ahead the week of 2026-06-12), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.5 years the stock moved +82% against the NIFTY 500's +267% — behind the index over the full window. — as of 11 September 2026.
Will Kaveri Seed Company Ltd's share price go up?
This page publishes no price forecast for Kaveri Seed Company Ltd. What it measures instead: the share price is ₹716, the price is in a downtrend 49 weeks in. Its P/E of 14.8× sits at the 45th percentile of its own 11-year range. — as of 11 September 2026.
Who owns Kaveri Seed Company Ltd?
Promoters hold 60.5% of Kaveri Seed Company Ltd, foreign institutions 17.5%, domestic institutions 3.5% and the public 17.7% (latest quarter). The biggest move on the register over the last two years: Domestic institutions cut 1.5 points over 8 quarters. — as of 11 September 2026.
Does Kaveri Seed Company Ltd have too much debt?
No — Kaveri Seed Company Ltd's debt-to-equity is 0.00, and operating profit covers the interest bill north of 100×. FY26 borrowings were ₹0.0 Cr against equity of ₹1,756 Cr. The returns on this page are earned, not borrowed — as of 11 September 2026.
What is Kaveri Seed Company Ltd's capex?
Kaveri Seed Company Ltd spent ₹296 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹115 Cr, with ₹130 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 11 September 2026.
What is Kaveri Seed Company Ltd's cash flow?
Kaveri Seed Company Ltd consumed ₹6.0 Cr of operating cash in FY26 — cash flowed out rather than in (free cash flow: ₹−121 Cr). Operating cash was negative while the company reported a profit of ₹296 Cr. Cash-flow resolution for India is annual. — as of 11 September 2026.
Is Kaveri Seed Company Ltd's profit real cash?
Mostly — over the last 3 fiscal years, 66% of Kaveri Seed Company Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹−6.0 Cr against reported profit of ₹296 Cr. The cash then goes mostly into the working-capital cycle. Cash-flow resolution is annual — as of 11 September 2026.
Where is Kaveri Seed Company Ltd in its business cycle?
Kaveri Seed Company Ltd's FY26 operating margin was 24.0%, against a 13-year band of 20.0%–29.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 40.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 11 September 2026.
What could break the Kaveri Seed Company Ltd story?
The sharpest disagreement: annual EPS moved +5.2% against a −37.5% price move — the market has not yet caught up with the delivery. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 11 September 2026.
Is Kaveri Seed Company Ltd a stock worth studying right now?
This is not investment advice. The machine read: Kaveri Seed Company Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: whether the price catches up with earnings that have already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 11 September 2026.
Not SEBI Registered !! Not Investment advice !!